Tag:Biosimilars

Professor Lietzan Speaks on Panel at Supreme Court IP Review

November 6th, 2017

Professor Erika Lietzan recently served as a panelist at the Supreme Court IP Review held at the Chicago-Kent College of Law. She discussed Sandoz, Inc. v. Amgen. Inc., a case decided by the Supreme Court last June.

Read More

Professor Lietzan Hosts Webinar for Pharmacists and Physicians

November 17th, 2015

Professor Erika Lietzan recently gave legal guidance for pharmacists and physicians in a Wolters Kluwer Clinical Drug Information webinar. Professor Lietzan drew on her expertise in biosimilars to guide the discussion and give pharmacists the top five

Read More

Professor Lietzan Cowrites Chapter in FDA in the 21st Century

September 10th, 2015

Professor Erika Lietzan recently cowrote an essay in a book published by Columbia University Press, FDA in the 21st Century, with Professor Henry Grabowski of Duke University. The book chapter, “FDA Regulation of Biosimilars,” discusses the Biologics

Read More

Professor Lietzan Publishes on Regulation of Biosimilars and Biotechnology Drugs, Devices

May 27th, 2015

Professor Erika Lietzan is the editor of a recently-published book on premarket and postmarket regulation of biotechnology drugs and devices. The book, Medical Biotechnology: Premarket and Postmarket Regulation, contains a chapter co-authored by Professor Lietzan that focuses

Read More

Professor Lietzan Discusses Biosimilars in Journal

February 17th, 2015

Professor Erika Lietzan was recently quoted in an article in the journal Nature Medicine about biosimilars, or “generic versions” of intricate drugs called “biologics,” according to the article. Professor Lietzan discussed the complicated patent process between the

Read More